NCT00786201 - A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Pulmonary Fibrosis

Interventions

DRUG

Placebo

Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48

DRUG

CNTO 888 1 mg/kg

IV infusion every 4 weeks, from Week 0 through Week 48

DRUG

CNTO 888 5 mg/kg

IV infusion every 4 weeks, from Week 0 through Week 48

DRUG

CNTO 888 15 mg/kg

IV infusion every 4 weeks, from Week 0 through Week 48

Trial Locations (30)

Unknown

Birmingham

Phoenix

Miami

Tampa

Chicago

Wichita

New Orleans

Ann Arbor

Minneapolis

Cincinnati

Philadelphia

Pittsburgh

Charleston

Spartanburg

Nashville

Salt Lake City

Colchester

Leuven

Edmonton

Winnipeg

Halifax

Hamilton

London

Vancouver

Bad Berka

Essen

Amsterdam

Nieuwegein

Rotterdam

Sittard